Living Well with MS – Invisible Symptoms, Health Routines and Digital Technology

This study will explore the strategies people with MS use to manage living with unpredictable (and often invisible) symptoms. It will ask about your experience with healthcare and explore how technology may help you manage your MS. The first phase of the project is this 10-minute survey. At the end of the survey, you will […]

Motoneurons, muscle weakness and motor performance in multiple sclerosis

In MS, muscle weakness is common and can affect everyday activities and quality of life. Impaired firing of spinal motor nerves (nerve fibres that activate limb muscles) may contribute to poor muscle function and movement in individuals living with MS. In these spinal motor nerves, special properties known as ‘persistent inward currents’ help them to […]

Exploring the use and need for lifestyle management of multiple sclerosis

This study is a survey of people living with Multiple Sclerosis to explore the use of lifestyle factors such as nutrition, exercise and stress management for symptom management. It will investigate the need for information, priorities for lifestyle areas and opinions in relation health care support for this form of self-management.

Project BASE: Changing Behaviour towards Aerobic and Resistance Exercise

Engaging in physical activity is beneficial to the wellbeing of people with MS. The aim of the study is to assess the feasibility of a study designed to involve people with MS in an exercise program. You’ll take part in a four-month at home exercise program, guided by our team of BASE physiotherapists, occupational therapists […]

Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial

To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]